Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

myTomorrows and brainstrust Partner to Support the Brain Cancer Community in Accessing Clinical Trials


News provided by

myTomorrows

04 Apr, 2024, 14:00 IDT

Share this article

Share toX

Share this article

Share toX

Partnership with the UK-based patient advocacy group furthers myTomorrows' mission to expand access to clinical trials for patients suffering from a variety of life-threatening illnesses, and support physicians in recruiting patients for clinical trials

AMSTERDAM , April 4, 2024 /PRNewswire/ -- myTomorrows, a global health technology company connecting patients with all possible treatment options, today announced a new partnership with brainstrust, a UK-based charity that helps people living with a brain tumor reach their potential and thrive. Under the new partnership, people with brain tumors will be equipped with the means to bolster their knowledge of relevant treatment options, potentially extending to participation in clinical trials and access to pre-approval drugs. Moreover, the partnership provides a new layer of support to clinicians in their efforts to recruit patients to relevant clinical trials.

There are 80,000 people living with a brain tumor in England alone, with a patient receiving a diagnosis every two hours. Brain tumors kill more children and adults under the age of 40 than any other cancer, and incidences and deaths from brain tumors are on the rise.

With only 12% of brain tumor patients surviving beyond five years of their diagnosis, it is crucial for these patients to be as robustly and accurately informed as possible in their search for treatment options – especially when it comes to clinical trials, as it is often difficult to find and understand relevant information about them.

brainstrust will now be able to provide its sizeable patient network with timely, up to date and useful information about credible and accessible clinical trials, with expert support from myTomorrows. myTomorrows' trained patient navigators will act as a single point of contact to guide patients with brain tumors, their loved ones, and healthcare professionals through the vast landscape of medical care and help them make the best possible decision during their treatment journey.

"We are very excited to be partnering with brainstrust, which boasts years of experience supporting and educating patients with brain cancer about many different aspects of their disease. Our collaboration aims to empower these patients to navigate their treatment journeys with more confidence and options," said Michel van Harten, CEO of myTomorrows. "Collaborating with leading patient advocacy organizations like brainstrust allows myTomorrows to extend our reach to patients affected by numerous conditions. This partnership forms part of our overall mission to raise patients' and physicians' awareness of different treatment options while enabling pharmaceutical companies to expand access throughout the drug development cycle."

"This is a very helpful and meaningful collaboration for the brain tumor community," said Helen Bulbeck, Director of Policy and Services, brainstrust. "This partnership means that people can build on the confidence and focus they have gained through their coaching with brainstrust and apply it to securing access to tangible options with the support of myTomorrows. People can be assured that they have turned every stone on their brain tumor journey and that they are working towards their best possible outcome."

The myTomorrows platform offers access to clinical trial information that patients and their physicians can discuss thoroughly, weighing the risks and benefits, before deciding if applying for a clinical trial is right for them.

To learn more about possible clinical trials, people impacted by brain tumours including patients, their caregivers or physicians can contact us here.

About myTomorrows:

myTomorrows is a digital platform that helps patients and physicians discover and access treatments. The myTomorrows platform conducts a comprehensive search of databases worldwide to provide patients and physicians with possible pre-approval treatment options. myTomorrows also offers biopharmaceutical companies services such as clinical trial recruitment support, international expanded access programs management and real-world data collection and utilization. Headquartered in Amsterdam with an office in New York City, myTomorrows has helped more than 5,000 patients and 500 physicians in over 80 countries to date. www.mytomorrows.com.

myTomorrows Media Contact:
Ben Crome
Headline Media
[email protected]
+1 914 336 4922

About brainstrust:

brainstrust is a UK-based charity dedicated to providing essential support and information to brain tumor patients and their families, and to supporting clinical research. With a mission to improve the quality of life for those affected by brain tumors, brainstrust offers a range of services, including coaching, patient and carer information, peer support, rapid-access counselling, and skills development for patients, their families and health care professionals.

By building communities, providing services and raising awareness, brainstrust makes a positive impact on the lives of individuals facing the challenges of brain tumors. People feel less alone, less afraid, more in control, better resourced, and more confident engaging with their clinical care.

www.brainstrust.org.uk

brainstrust Media Contact:
Will Jones
Chief Executive
07855 987340
[email protected]

Modal title

Also from this source

myTomorrows Expands AI Capabilities to Support Clinical Trial Sites, Streamline Trial Recruitment and Strengthen Site Workflows

myTomorrows, a global health technology company connecting patients with all possible pre-approval treatments, today announced a new solution to...

Over 275 Duchenne Patients Enrolled in Pre-Approval Treatment Programs Around the World with myTomorrows' Platform

myTomorrows, a global health technology company connecting patients with all possible pre-approval treatments, announced today that it has referred...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Computer & Electronics

Computer & Electronics

Medical Equipment

Medical Equipment

News Releases in Similar Topics

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.